Despite these encouraging results, relapse with BCMA-negative tumors have been reported in several studies clearly highlighting antigen-escape as an emerging obstacle for the curative potential of anti-BCMA CAR T-cells in myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.